N-Acetylcysteine: The Next Best Thing for Cardiovascular Interventions and Surgery?
- PMID: 38547513
- DOI: 10.1097/FJC.0000000000001558
N-Acetylcysteine: The Next Best Thing for Cardiovascular Interventions and Surgery?
Conflict of interest statement
The authors report no conflicts of interest.
Comment on
-
N-Acetylcysteine to Reduce Mortality for Patients Requiring Cardiac Catheterization or Cardiac Surgery: A Systematic Review and Meta-analysis.J Cardiovasc Pharmacol. 2024 Jun 1;83(6):580-587. doi: 10.1097/FJC.0000000000001551. J Cardiovasc Pharmacol. 2024. PMID: 38467037
References
-
- Matteucci A, Bonanni M, Versaci F, et al. Cardiovascular medicine: a year in review. Minerva Cardiol Angiol. 2022;70:40–55.
-
- Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2:e124.
-
- Biondi-Zoccai GG, Lotrionte M, Abbate A, et al. Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. BMJ. 2006;332:202–209.
-
- Biondi-Zoccai GG, Abbate A, Valgimigli M, et al. From chaotic to coordinated clinical research: the case of acetylcysteine. Arch Intern Med. 2006;166:1668.
-
- Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180–184.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources